Latest Conference Articles

A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.

Data presented at the 2023 European Hematology Association Annual Meeting showed positive outcomes in patients with follicular lymphoma and large B-cell lymphoma, and further evaluation in diffuse large B-cell lymphoma is ongoing.

Andy Blauvelt, MD, MBA, president of Oregon Medical Research Center, discusses challenges many physicians face in getting approved for the most effective drugs to treat patients with atopic dermatitis (AD).

In this interview from SLEEP 2023, Andrew McHill, PhD, of Oregon Health and Science University (OHSU), explains the importance of individualizing sleep hygiene recommendations.

The therapy is designed to target multiple receptors and could address an unmet need in metastatic colorectal cancer.

A second study will evaluate the treatment and financial burden and quality of life of a program of subcutaneous daratumumab administered at home.

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

Susan Escudier, MD, FACP, vice president of value-based and quality programs for Texas Oncology, discusses how collaboration between oncologists and primary care physicians (PCPs) can improve patient satisfaction and outcomes.

In this interview from SLEEP 2023, Dayna Johnson, PhD, MPH, MSW, MS, addresses the various pathways through which cardiovascular health is adversely affected by suboptimal sleep health.

Courtney DiNardo, MD, MSCE, the lead author on a study presented at EHA 2023 evaluating a new therapy for chronic myelomonocytic leukemia and acute myeloid leukemia, discusses the FDA Fast Track Designation for IO-202 and strategies for raising awareness and improving diversity in clinical trials.

Panelists provided a wide-ranging view of the current avenues being investigated to optimize the treatment of chronic lymphocytic leukemia (CLL), including minimal residual disease assessment, combination regimens, and chimeric antigen receptor T-cell therapy.

Martin Griesshammer, MD, PhD, from the Johannes Wesling University Clinic, spoke on the current unmet needs in treating polycythemia vera (PV) and how multistakeholder collaboration can help address them.

More data is emerging on the efficacy of several triplet therapies to treat single-class refractory multiple myeloma (MM), potentially giving patients more therapy options than ever before, according to Tel-Aviv Sourasky Medical Center's Yael Cohen, MD, at the European Hematology Association 2023 Congress.

Wojciech Jurczak, MD, PhD, lead researcher on the L-MIND study evaluating a new treatment combination in diffuse large B-cell lymphoma (DLBCL), gave an overview of the trial results that were presented at the European Hematology Association 2023 Congress.

The late-breaking oral session at the European Hematology Association (EHA) 2023 Congress featured newly emerged data from abstracts submitted after the deadline, including outcomes from trials in polycythemia vera, acute myeloid leukemia, and more.

Newly presented data reveal disparities between Black and White patients in both the characteristics of and the decision-making around treatment for chronic lymphocytic leukemia (CLL) and multiple myeloma, respectively.

With the number of treatment options in hematology and oncology rapidly expanding, so too are the strategies for determining and ensuring cost-effectiveness, according to session speakers at the European Hematology Association (EHA) 2023 Congress.

The first phase 3 results from the CARTITUDE-4 trial of ciltacabtagene autoleucel (cilta-cel) vs standard of care in lenalidomide-refractory multiple myeloma (MM) demonstrated the former’s convincing superiority in several key outcomes.

Results from the ASPEN and ALPINE trials of zanubrutinib showed greater improvements in quality of life (QOL) vs ibrutinib.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, shared her thoughts on the current research regarding Bruton tyrosine kinase (BTK) and B-cell lymphoma 2 (BCL-2) inhibitors in chronic lymphocytic leukemia (CLL) and what providers should keep in mind before prescribing them.

MD Anderson Cancer Center's Hans Lee, MD, shared considerations for possible infection risk associated with bispecific therapies used to treat relapsed/refractory multiple myeloma (MM) at the European Hematology Association 2023 Congress

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor outcomes compared with those without BRCA mutations and those with non-BRCA HRR mutations.

A friendly debate held at the European Hematology Association 2023 Congress focused on the potential for real-world data to improve the generalizability of clinical trial results but also acknowledged the limitations and current challenges with these data.

If payers can agree on consensus criteria to improve care quality or costs, that will help physicians remember and try to be compliant, said Samyukta Mullangi, MD, MBA, incoming medical director at Thyme Care.

The use of immune therapies for hematological malignancies is expanding beyond chimeric antigen receptor (CAR) T-cell therapies in the traditional lymphoid disease states, but the impact on patient quality of life must remain top of mind, according to speakers at the European Hematology Association 2023 Congress.

Watch and see what Michael Shapiro, DO, FASPC, president-elect of the American Society for Preventive Cardiology, wants you to know about this year's ASPC Congress on CVD Prevention.

Children with narcolepsy often have disrupted nighttime sleep (DNS), which could lead to other effects, such as memory issues.

In this interview with The American Journal of Managed Care®, Symielle A. Gaston, PhD, MPH, of the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health, explores the relationship between sleep health and outcomes disparities among patients of various races and ethnicities.

Panelists at SLEEP 2023 presented preliminary data on how sleep interventions could close the gap in treating Black children and families in sleep health.

Posters presented at the SLEEP 2023 conference showed that transition between medications was easy but 1 medication felt more effective to patients.